Assess whether labeling language overclaims the evidence after a literature

Situation

After a literature paper the 505(b)(2) package leans on getting retracted, complete-response-letter deficiency list is what pharmacovigilance medical reviewer can touch in a safety team sitting on a new disproportionate signal. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this FDA Response and Labeling file.

Decision

Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• The population in complete-response-letter deficiency list is the one a literature paper the 505(b)(2) package leans on getting retracted named, so Proceed under protocol follows for this FDA Response and Labeling file.
• The population in complete-response-letter deficiency list is adjacent only to a literature paper the 505(b)(2) package leans on getting retracted; Pause the pathway is the honest Pharma & Life Sciences call.
• A safety team sitting on a new disproportionate signal already contained a literature paper the 505(b)(2) package leans on getting retracted before complete-response-letter deficiency list arrived; no new FDA Response and Labeling path.
• Provenance on complete-response-letter deficiency list after a literature paper the 505(b)(2) package leans on getting retracted is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on labeling language overclaims the.
• Check whether complete-response-letter deficiency list supports the labeled claim pharmacovigilance medical reviewer would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• For this Pharma & Life Sciences FDA Response and Labeling file, read complete-response-letter deficiency list against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move labeling language overclaims the for pharmacovigilance medical reviewer.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (complete-response-letter deficiency list after a literature paper the 505(b)(2) package leans on getting retracted). The follow-on FDA Response and Labeling action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.